136 related articles for article (PubMed ID: 15276179)
1. Stop the killer: how to inhibit the anthrax lethal factor metalloprotease.
Montecucco C; Tonello F; Zanotti G
Trends Biochem Sci; 2004 Jun; 29(6):282-5. PubMed ID: 15276179
[TBL] [Abstract][Full Text] [Related]
2. The anthrax lethal factor and its MAPK kinase-specific metalloprotease activity.
Tonello F; Montecucco C
Mol Aspects Med; 2009 Dec; 30(6):431-8. PubMed ID: 19665472
[TBL] [Abstract][Full Text] [Related]
3. Consequences and utility of the zinc-dependent metalloprotease activity of anthrax lethal toxin.
Bromberg-White J; Lee CS; Duesbery N
Toxins (Basel); 2010 May; 2(5):1038-53. PubMed ID: 22069624
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the proteolytic activity of anthrax lethal factor by aminoglycosides.
Lee LV; Bower KE; Liang FS; Shi J; Wu D; Sucheck SJ; Vogt PK; Wong CH
J Am Chem Soc; 2004 Apr; 126(15):4774-5. PubMed ID: 15080670
[TBL] [Abstract][Full Text] [Related]
5. Potent inhibitors of anthrax lethal factor from green tea.
Dell'Aica I; Donà M; Tonello F; Piris A; Mock M; Montecucco C; Garbisa S
EMBO Rep; 2004 Apr; 5(4):418-22. PubMed ID: 15031715
[TBL] [Abstract][Full Text] [Related]
6. Low molecular weight inhibitors of the protease anthrax lethal factor.
Dalkas GA; Papakyriakou A; Vlamis-Gardikas A; Spyroulias GA
Mini Rev Med Chem; 2008 Mar; 8(3):290-306. PubMed ID: 18336349
[TBL] [Abstract][Full Text] [Related]
7. Anthrax lethal factor inhibitors as potential countermeasure of the infection.
Kumar BV; Malik S; Grandhi P; Dayam R; Sarma JA
Curr Top Med Chem; 2014; 14(17):1977-89. PubMed ID: 25262802
[TBL] [Abstract][Full Text] [Related]
8. Proteolytic assay-based screening identifies a potent inhibitor of anthrax lethal factor.
Park HC; Sung SR; Lim SM; Lee JS; Kim SK; Yoon MY
Microb Pathog; 2012 Aug; 53(2):109-12. PubMed ID: 22561400
[TBL] [Abstract][Full Text] [Related]
9. A novel pharmacophore model for the design of anthrax lethal factor inhibitors.
Yuan H; Johnson SL; Chen LH; Wei J; Pellecchia M
Chem Biol Drug Des; 2010 Sep; 76(3):263-8. PubMed ID: 20572812
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic differences between in vitro assays for hydrazone-based small molecule inhibitors of anthrax lethal factor.
Hanna ML; Tarasow TM; Perkins J
Bioorg Chem; 2007 Feb; 35(1):50-8. PubMed ID: 16949126
[TBL] [Abstract][Full Text] [Related]
11. The metalloproteolytic activity of the anthrax lethal factor is substrate-inhibited.
Tonello F; Ascenzi P; Montecucco C
J Biol Chem; 2003 Oct; 278(41):40075-8. PubMed ID: 12888555
[TBL] [Abstract][Full Text] [Related]
12. Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.
Schepetkin IA; Khlebnikov AI; Kirpotina LN; Quinn MT
J Med Chem; 2006 Aug; 49(17):5232-44. PubMed ID: 16913712
[TBL] [Abstract][Full Text] [Related]
13. Chemical genetic screening identifies critical pathways in anthrax lethal toxin-induced pathogenesis.
Panchal RG; Ruthel G; Brittingham KC; Lane D; Kenny TA; Gussio R; Lazo JS; Bavari S
Chem Biol; 2007 Mar; 14(3):245-55. PubMed ID: 17379140
[TBL] [Abstract][Full Text] [Related]
14. Yeast-hybrid based high-throughput assay for identification of anthrax lethal factor inhibitors.
Kim J; Park HC; Gedi V; Park HY; Roberts AG; Atkins WM; Yoon MY
Biochem Biophys Res Commun; 2011 Jan; 404(1):517-22. PubMed ID: 21144836
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of the Metalloproteinase Anthrax Lethal Factor.
Goldberg AB; Turk BE
Curr Top Med Chem; 2016; 16(21):2350-8. PubMed ID: 27072692
[TBL] [Abstract][Full Text] [Related]
16. Insilico studies on anthrax lethal factor inhibitors: pharmacophore modeling and virtual screening approaches towards designing of novel inhibitors for a killer.
Roy J; Kumar UC; Machiraju PK; Muttineni RK; Kumar B V S S; Gundla R; Dayam R; Sarma JA
J Mol Graph Model; 2010 Sep; 29(2):256-65. PubMed ID: 20727800
[TBL] [Abstract][Full Text] [Related]
17. Metalloproteinase inhibitors, nonantimicrobial chemically modified tetracyclines, and ilomastat block Bacillus anthracis lethal factor activity in viable cells.
Kocer SS; Walker SG; Zerler B; Golub LM; Simon SR
Infect Immun; 2005 Nov; 73(11):7548-57. PubMed ID: 16239558
[TBL] [Abstract][Full Text] [Related]
18. The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection.
Xiong Y; Wiltsie J; Woods A; Guo J; Pivnichny JV; Tang W; Bansal A; Cummings RT; Cunningham BR; Friedlander AM; Douglas CM; Salowe SP; Zaller DM; Scolnick EM; Schmatz DM; Bartizal K; Hermes JD; MacCoss M; Chapman KT
Bioorg Med Chem Lett; 2006 Feb; 16(4):964-8. PubMed ID: 16338135
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel anthrax lethal factor inhibitors generated by combinatorial Pictet-Spengler reaction followed by screening in situ.
Numa MM; Lee LV; Hsu CC; Bower KE; Wong CH
Chembiochem; 2005 Jun; 6(6):1002-6. PubMed ID: 15880659
[No Abstract] [Full Text] [Related]
20. Purification and biophysical characterization of the core protease domain of anthrax lethal factor.
Gkazonis PV; Dalkas GA; Chasapis CT; Vlamis-Gardikas A; Bentrop D; Spyroulias GA
Biochem Biophys Res Commun; 2010 Jun; 396(3):643-7. PubMed ID: 20438702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
